Editas Medicine (NASDAQ: EDIT) reported Q4 EPS of ($0.55), $0.22 worse than the analyst estimate of ($0.33). Revenue for the quarter came in at $30.6 million versus the consensus estimate of $29.59 million.

For earnings history and earnings-related data on Editas Medicine (EDIT) click here.